Developer docs
API playgroundTry for free, no card

Search company profiles

Scohia Pharma

Full company profile

uuid0002yho

Namestring
Scohia Pharma
Legal namestring
株式会社スコヒアファーマ (SCOHIA PHARMA, Inc.)
Websiteurl
scohia.com
Company typeenum
Private
Founded yearint
2017
Short descriptiontext

Scohia Pharma is a Japanese specialty biotech, founded in 2017 as a Takeda carve-out, that discovers and out-licenses first-in-class small molecule and peptide drug candidates for endocrine, cardiovascular, renal, and metabolic diseases to global pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersFujisawa, Japan
HQ citystring
Fujisawa
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery services, metabolic disease therapeutics, out-licensing pipelines, small molecule discovery, peptide drug discovery
Industry4 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Drug Discovery & Pharmaceutical R&D
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1License upfront payments
TypeLicensing Royalties
Description

Scohia receives upfront payments upon signing licensing agreements with partners. For SCO-483, Neurocrine Biosciences paid a $20 million upfront.

scohia.com
2R&D milestone payments
TypeLicensing Royalties
Description

The company earns milestone payments tied to achievement of specific development and regulatory milestones. For SCO-483, up to $550 million in potential milestones were agreed.

scohia.com
3Sales royalties
TypeLicensing Royalties
Description

Scohia receives tiered royalties on worldwide net sales of partnered products, ranging from single-digit to low double-digit percentages depending on the agreement.

scohia.com
4Third-party equity financing
TypeLicensing Royalties
Description

The company raises equity capital through third-party allotments to fund R&D operations. Most recent financing raised JPY 3.0 billion (May 2026).

scohia.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Scohia Pharma discovers and develops proprietary small molecule and peptide drug candidates targeting endocrine, cardiovascular, renal, and metabolic diseases. The company retains discovery and preclinical capabilities in-house while out-licensing clinical development, manufacturing, and commercialization rights to global pharmaceutical partners through licensing agreements that generate upfront payments, development and sales milestones, and tiered royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • SCO-240 achieved sustained IGF-1 elevation in Phase 1 MAD study across all dose groups (3-80mg) with favorable safety profile — first clinical demonstration of oral SSTR5 antagonist-induced GH stimulation in humans
+2 more records
Product overview1 text field

Scohia Pharma is a specialty bioventure focused on drug discovery for lifestyle-related diseases in cardiovascular, metabolic, renal, and endocrine therapeutic areas. The company operates a diversified pipeline of drug candidates spanning multiple mechanisms of action: Core Pipeline includes SCO-240 (SSTR5 antagonist) and SCO-792 (enteropeptidase inhibitor) in clinical stages. Value-Added Pipeline comprises SCO-272 (renin inhibitor), SCO-267 (GPR40 agonist), SCO-006 (IP6K inhibitor), and SCO-116 (NRF2 activator). Partnered Pipeline includes SCO-094 (GLP-1R/GIPR dual agonist, licensed to Huadong Medicine), SCO-940/CT-G32 (quadruple agonist, partnered with Celltrion), SCO-483 (MC2R antagonist, licensed to Neurocrine Biosciences), and SCO-116 for ophthalmic/dermal use (licensed to Kuria Therapeutics). The company leverages small molecule and peptide engineering capabilities, focusing on areas with high unmet medical needs including rare diseases and obesity.

Product and service9 records
1SCO-240
CategoryClinical-stage drug candidate (Core Pipeline)
Description

First-in-class orally available somatostatin receptor type 5 (SSTR5) antagonist that selectively stimulates growth hormone secretion in humans without affecting other pituitary hormones. In clinical development for growth hormone deficiency, with potential applications in infertility and alopecia.

2SCO-792
CategoryClinical-stage drug candidate (Core Pipeline)
Description

First-in-class orally available enteropeptidase inhibitor that blocks gut amino acid absorption. In development for autosomal dominant polycystic kidney disease (ADPKD), phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystinuria (HCU), and diabetic kidney disease.

3SCO-272 (Imarikiren)
CategoryPreclinical/clinical-stage drug candidate (Value-Added Pipeline)
Description

Long-acting direct renin inhibitor available as oral and injectable formulation. In development for diabetic kidney disease and hypertension.

4SCO-267
CategoryPreclinical/clinical-stage drug candidate (Value-Added Pipeline)
Description

First-in-class GPR40 full agonist with new chemical structure binding to a site independent of fasiglifam. Stimulates islet and gut hormones including GLP-1, GIP, PYY, and glucagon. In development for diabetes, obesity, and NASH.

5SCO-006
CategoryPreclinical-stage drug candidate (Value-Added Pipeline)
Description

First-in-class orally bioavailable IP6K (inositol hexakisphosphate kinase) inhibitor that decreases plasma phosphate levels by blocking cellular phosphate export. In development for hyperphosphatemia, chronic kidney disease, and ovarian clear cell carcinoma.

6SCO-116
CategoryPreclinical-stage drug candidate (Partnered Pipeline)
Description

Novel NRF2 activator that selectively inhibits the NRF2-KEAP1 protein-protein interaction. Available as oral or injectable form. In development for diabetic kidney disease, chronic kidney disease, lung diseases, and eye diseases.

7SCO-094
CategoryPartnered drug candidate (Clinical-stage)
Description

GLP-1R/GIPR dual agonist demonstrating superior efficacy to GLP-1 mono-agonists in preclinical studies. Licensed exclusively to Huadong Medicine for worldwide development and commercialization for obesity, diabetes, and NASH.

8SCO-940/CT-G32
CategoryPartnered drug candidate (Preclinical-stage)
Description

First-in-class next-generation quadruple agonist for obesity and metabolic diseases developed in collaboration with Celltrion. Scohia leads drug discovery and preclinical development through IND submission; Celltrion is responsible for clinical development, regulatory interactions, manufacturing, and worldwide commercialization.

9SCO-483 (NBI-1852737)
CategoryPartnered drug candidate (Preclinical/clinical-stage)
Description

Selective melanocortin 2 receptor (MC2R) antagonist targeting overactive ACTH signaling. Licensed exclusively to Neurocrine Biosciences for worldwide development, manufacturing, and commercialization for congenital adrenal hyperplasia (CAH), ACTH-dependent Cushing's syndrome, and rare metabolic diseases.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-04-10
Description

Exclusive worldwide license agreement for SCO-483 (selective MC2R antagonist, Neurocrine development code NBI-1852737) for rare metabolic diseases including congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. Scohia received $20M upfront and is eligible for up to $550M in milestones plus tiered royalties (single to low double-digit % on worldwide net sales).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-03
Description

Strategic collaboration initiated in 2024 for next-generation obesity treatments. Scohia leads drug discovery and preclinical development through IND submission (targeted H1 2027); Celltrion is responsible for clinical development, regulatory interactions, manufacturing, and worldwide commercialization of SCO-940 (CT-G32), a first-in-class quadruple agonist. Scohia eligible for multiple R&D milestones and single-digit % royalties on global net sales.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-06-27
Description

Strategic licensing agreement for SCO-116 (novel NRF2 activator) in ophthalmic and dermatological diseases for topical administration. Kuria Therapeutics acquired rights for eye diseases (Fuchs' Dystrophy, corneal endothelial damage, dry AMD) and skin diseases.

4Huadong Medicine (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-06-01
Description

Worldwide exclusive license for SCO-094 (GLP-1R/GIPR dual agonist) for the treatment of obesity, diabetes, and NASH. Collaboration was first established in Asia Pacific in 2021 and expanded globally in 2023. Huadong Medicine is conducting Phase 1 trials in the UK.

scohia.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global incumbent leading diabetes/obesity therapy markets with Ozempic/Wegovy; defines the standard of care that Scohia's metabolic and renal pipeline must compete against or complement.

2PeptiDream
TypeDirect peer
Description

Japanese peptide drug discovery company with proprietary peptide platform and broad pharma licensing partnerships. Comparable Japan-based, discovery-stage, peptide-focused out-licensing model; both work on low-and-medium molecular weight peptides.

TypeBroad incumbent
Description

Global pharmaceutical incumbent dominating the cardiometabolic/obesity space via Mounjaro/Zepbound; sets the competitive benchmark against which Scohia's GLP-1/GIP/quadruple agonists must differentiate.

TypeDirect peer
Description

US clinical-stage biotech focused on rare endocrine diseases (acromegaly, congenital hyperinsulinism) with a similar licensing/specialty-pharma profile and small specialized team — closely comparable in therapeutic area focus and discovery-stage business model.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics for hematological and musculoskeletal disorders with similar venture-backed profile and multiple partnered programs. Comparable size and clinical-stage development posture.

TypeDirect peer
Description

Specialty biotech developing first-in-class therapies for NASH and metabolic liver disease with strategic focus on lifestyle-related metabolic indications — directly overlaps Scohia's SCO-267 NASH and broader metabolic disease thesis.

TypeBroad incumbent
Description

Japan-headquartered global pharma and former parent company of Scohia (2017 carve-out). Provides historical IP foundation and connection to founders' blockbuster drug discovery track record.

TypeBroad incumbent
Description

Major Japanese pharmaceutical incumbent with metabolic, renal, and rare disease franchises; relevant as a possible future licensing partner or acquirer for Scohia's pipeline assets.

TypeBroad incumbent
Description

Japan-headquartered global pharmaceutical company with cardiovascular and metabolic portfolios and active out-licensing of large-molecule and small-molecule programs — comparable Japan-based discovery-to-commercial pathway.

TypeOthers
Description

Strategic licensing partner for SCO-483 and a US specialty pharma with a CNS/endocrinology focus. Comparable positioning in rare endocrine diseases (congenital adrenal hyperplasia, Cushing's syndrome) where SCO-483 is being advanced.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scohia Pharma

Drug Discovery & Pharmaceutical R&Dscohia.com

Scohia Pharma is a Japanese specialty biotech, founded in 2017 as a Takeda carve-out, that discovers and out-licenses first-in-class small molecule and peptide drug candidates for endocrine, cardiovascular, renal, and metabolic diseases to global pharmaceutical partners.

Scohia Pharma firmographics

Firmographics
Name
Scohia Pharma
Legal name
株式会社スコヒアファーマ (SCOHIA PHARMA, Inc.)
Website
https://scohia.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Scohia Pharma is a Japanese specialty biotech, founded in 2017 as a Takeda carve-out, that discovers and out-licenses first-in-class small molecule and peptide drug candidates for endocrine, cardiovascular, renal, and metabolic diseases to global pharmaceutical partners.
Ownership category
akta.pro rank

Scohia Pharma industry classification

Industry
Product category
Drug Discovery & Pharmaceutical R&D
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Drug discovery services
  • Metabolic disease therapeutics
  • Out-licensing pipelines
  • Small molecule discovery
  • Peptide drug discovery

Where Scohia Pharma is headquartered

Location

Headquarters

HQ city
Fujisawa
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

Scohia Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. License upfront payments: Scohia receives upfront payments upon signing licensing agreements with partners. For SCO-483, Neurocrine Biosciences paid a $20 million upfront.
  2. R&D milestone payments: The company earns milestone payments tied to achievement of specific development and regulatory milestones. For SCO-483, up to $550 million in potential milestones were agreed.
  3. Sales royalties: Scohia receives tiered royalties on worldwide net sales of partnered products, ranging from single-digit to low double-digit percentages depending on the agreement.
  4. Third-party equity financing: The company raises equity capital through third-party allotments to fund R&D operations. Most recent financing raised JPY 3.0 billion (May 2026).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Scohia Pharma product offering

Product offering

Core offering

Scohia Pharma discovers and develops proprietary small molecule and peptide drug candidates targeting endocrine, cardiovascular, renal, and metabolic diseases. The company retains discovery and preclinical capabilities in-house while out-licensing clinical development, manufacturing, and commercialization rights to global pharmaceutical partners through licensing agreements that generate upfront payments, development and sales milestones, and tiered royalties.

Product overview

Scohia Pharma is a specialty bioventure focused on drug discovery for lifestyle-related diseases in cardiovascular, metabolic, renal, and endocrine therapeutic areas. The company operates a diversified pipeline of drug candidates spanning multiple mechanisms of action: Core Pipeline includes SCO-240 (SSTR5 antagonist) and SCO-792 (enteropeptidase inhibitor) in clinical stages. Value-Added Pipeline comprises SCO-272 (renin inhibitor), SCO-267 (GPR40 agonist), SCO-006 (IP6K inhibitor), and SCO-116 (NRF2 activator). Partnered Pipeline includes SCO-094 (GLP-1R/GIPR dual agonist, licensed to Huadong Medicine), SCO-940/CT-G32 (quadruple agonist, partnered with Celltrion), SCO-483 (MC2R antagonist, licensed to Neurocrine Biosciences), and SCO-116 for ophthalmic/dermal use (licensed to Kuria Therapeutics). The company leverages small molecule and peptide engineering capabilities, focusing on areas with high unmet medical needs including rare diseases and obesity.

Differentiator

Problem solved

Functional benefit

Products and services

  • SCO-240 First-in-class orally available somatostatin receptor type 5 (SSTR5) antagonist that selectively stimulates growth hormone secretion in humans without affecting other pituitary hormones. In clinical development for growth hormone deficiency, with potential applications in infertility and alopecia.
  • SCO-792 First-in-class orally available enteropeptidase inhibitor that blocks gut amino acid absorption. In development for autosomal dominant polycystic kidney disease (ADPKD), phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystinuria (HCU), and diabetic kidney disease.
  • SCO-272 (Imarikiren) Long-acting direct renin inhibitor available as oral and injectable formulation. In development for diabetic kidney disease and hypertension.
  • SCO-267 First-in-class GPR40 full agonist with new chemical structure binding to a site independent of fasiglifam. Stimulates islet and gut hormones including GLP-1, GIP, PYY, and glucagon. In development for diabetes, obesity, and NASH.
  • SCO-006 First-in-class orally bioavailable IP6K (inositol hexakisphosphate kinase) inhibitor that decreases plasma phosphate levels by blocking cellular phosphate export. In development for hyperphosphatemia, chronic kidney disease, and ovarian clear cell carcinoma.
  • SCO-116 Novel NRF2 activator that selectively inhibits the NRF2-KEAP1 protein-protein interaction. Available as oral or injectable form. In development for diabetic kidney disease, chronic kidney disease, lung diseases, and eye diseases.
  • SCO-094 GLP-1R/GIPR dual agonist demonstrating superior efficacy to GLP-1 mono-agonists in preclinical studies. Licensed exclusively to Huadong Medicine for worldwide development and commercialization for obesity, diabetes, and NASH.
  • SCO-940/CT-G32 First-in-class next-generation quadruple agonist for obesity and metabolic diseases developed in collaboration with Celltrion. Scohia leads drug discovery and preclinical development through IND submission; Celltrion is responsible for clinical development, regulatory interactions, manufacturing, and worldwide commercialization.
  • SCO-483 (NBI-1852737) Selective melanocortin 2 receptor (MC2R) antagonist targeting overactive ACTH signaling. Licensed exclusively to Neurocrine Biosciences for worldwide development, manufacturing, and commercialization for congenital adrenal hyperplasia (CAH), ACTH-dependent Cushing's syndrome, and rare metabolic diseases.

Quantifiable outcome

  • SCO-240 achieved sustained IGF-1 elevation in Phase 1 MAD study across all dose groups (3-80mg) with favorable safety profile — first clinical demonstration of oral SSTR5 antagonist-induced GH stimulation in humans
  • +2 more outcomes

Companies that use Scohia Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Scohia Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Scohia Pharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Neurocrine Biosciences (via Neurocrine Switzerland GmbH)coreOEM/ Whitelabel/ Licensing Partner · 10 April 2024Exclusive worldwide license agreement for SCO-483 (selective MC2R antagonist, Neurocrine development code NBI-1852737) for rare metabolic diseases including congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. Scohia received $20M upfront and is eligible for up to $550M in milestones plus tiered royalties (single to low double-digit % on worldwide net sales).
  • Celltrion, Inc.coreStrategic or Co-development Partner · 3 April 2024Strategic collaboration initiated in 2024 for next-generation obesity treatments. Scohia leads drug discovery and preclinical development through IND submission (targeted H1 2027); Celltrion is responsible for clinical development, regulatory interactions, manufacturing, and worldwide commercialization of SCO-940 (CT-G32), a first-in-class quadruple agonist. Scohia eligible for multiple R&D milestones and single-digit % royalties on global net sales.
  • Kuria TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 27 June 2022Strategic licensing agreement for SCO-116 (novel NRF2 activator) in ophthalmic and dermatological diseases for topical administration. Kuria Therapeutics acquired rights for eye diseases (Fuchs' Dystrophy, corneal endothelial damage, dry AMD) and skin diseases.
  • Huadong Medicine (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)coreOEM/ Whitelabel/ Licensing Partner · 1 June 2021Worldwide exclusive license for SCO-094 (GLP-1R/GIPR dual agonist) for the treatment of obesity, diabetes, and NASH. Collaboration was first established in Asia Pacific in 2021 and expanded globally in 2023. Huadong Medicine is conducting Phase 1 trials in the UK.

Scale indicators3 records

Recent moves8 records

Expansion highlights4 records

Scohia Pharma competitors and assessment

Company assessment

Broad incumbents

  • Novo Nordisk: Global incumbent leading diabetes/obesity therapy markets with Ozempic/Wegovy; defines the standard of care that Scohia's metabolic and renal pipeline must compete against or complement.
  • Eli Lilly: Global pharmaceutical incumbent dominating the cardiometabolic/obesity space via Mounjaro/Zepbound; sets the competitive benchmark against which Scohia's GLP-1/GIP/quadruple agonists must differentiate.
  • Takeda Pharmaceutical: Japan-headquartered global pharma and former parent company of Scohia (2017 carve-out). Provides historical IP foundation and connection to founders' blockbuster drug discovery track record.
  • Astellas Pharma: Major Japanese pharmaceutical incumbent with metabolic, renal, and rare disease franchises; relevant as a possible future licensing partner or acquirer for Scohia's pipeline assets.
  • Daiichi Sankyo: Japan-headquartered global pharmaceutical company with cardiovascular and metabolic portfolios and active out-licensing of large-molecule and small-molecule programs — comparable Japan-based discovery-to-commercial pathway.

Direct peers

  • PeptiDream: Japanese peptide drug discovery company with proprietary peptide platform and broad pharma licensing partnerships. Comparable Japan-based, discovery-stage, peptide-focused out-licensing model; both work on low-and-medium molecular weight peptides.
  • Crinetics Pharmaceuticals: US clinical-stage biotech focused on rare endocrine diseases (acromegaly, congenital hyperinsulinism) with a similar licensing/specialty-pharma profile and small specialized team — closely comparable in therapeutic area focus and discovery-stage business model.
  • Keros Therapeutics: Clinical-stage biotech developing therapeutics for hematological and musculoskeletal disorders with similar venture-backed profile and multiple partnered programs. Comparable size and clinical-stage development posture.
  • Madrigal Pharmaceuticals: Specialty biotech developing first-in-class therapies for NASH and metabolic liver disease with strategic focus on lifestyle-related metabolic indications — directly overlaps Scohia's SCO-267 NASH and broader metabolic disease thesis.

Others

  • Neurocrine Biosciences: Strategic licensing partner for SCO-483 and a US specialty pharma with a CNS/endocrinology focus. Comparable positioning in rare endocrine diseases (congenital adrenal hyperplasia, Cushing's syndrome) where SCO-483 is being advanced.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Scohia Pharma social profiles

Digital presence

Scohia Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scohia Pharma leadership team

Management profile

Number of profiles

Profiles14 records

Scohia Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scohia Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scohia Pharma

What does Scohia Pharma do?

Scohia Pharma discovers and develops proprietary small molecule and peptide drug candidates targeting endocrine, cardiovascular, renal, and metabolic diseases. The company retains discovery and preclinical capabilities in-house while out-licensing clinical development, manufacturing, and commercialization rights to global pharmaceutical partners through licensing agreements that generate upfront payments, development and sales milestones, and tiered royalties.

Is Scohia Pharma a public or private company?

Scohia Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Scohia Pharma founded?

Scohia Pharma was founded in 2017. It employs 1 to 10 people.

Where is Scohia Pharma based?

Scohia Pharma is headquartered in Fujisawa, Japan, in the Asia region.

How does Scohia Pharma make money?

Four revenue lines are on record. License upfront payments are the primary driver. The others are R&D milestone payments, sales royalties and third-party equity financing.

Who are Scohia Pharma's main competitors?

Broad incumbents on record are Novo Nordisk, Eli Lilly, Takeda Pharmaceutical, Astellas Pharma and Daiichi Sankyo. Direct peers are PeptiDream, Crinetics Pharmaceuticals, Keros Therapeutics and Madrigal Pharmaceuticals. Neurocrine Biosciences is listed as an others.

Does Scohia Pharma have an API?

No public API is recorded for Scohia Pharma.

What industry is Scohia Pharma in?

Scohia Pharma's product category is Drug Discovery & Pharmaceutical R&D. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals